Healthgen Obtains CMMM Level 3 Certification

ISSCR 2026-Healthgen Biotech showcases rice-derived rHSA

Healthgen Biotech continues to deepen its footprint in stem cell and regenerative medicine, actively advancing global standards for serum-free culture systems, CGT process quality control, and clinical compliance.

Healthgen Biotech to attend KOREA PHARM & BIO 2026

31th March to 3rd April. Gyeonggi-do,Seoul

Healthgen Announces Listing on October 28, 2025

(Stock Name: Healthgen Biotech; Stock Code: 688765) Shanghai Stock Exchange, the first listed company specializing in recombinant human albumin.

Gut commentary highlighting the significant clinical implications of Olbumin®

The authoritative international hepatology journal Gut published a commentary highlighting the significant clinical implications of Recombinant Human Albumin Injection (Oryza Sativa)in albumin therapy

Olbumin® receives approval to initiate Phase III Clinical Trials in US

Recombinant Human Albumin Injection (Oryza Sativa) receives approval to initiate Phase III Clinical Trials in the United States

OsrHSA Listed as MIIT Landmark Biomanufacturing Product

Recombinant Human Albumin(Oryza sativa) Selected into List of Landmark Biomanufacturing Products by the Ministry of Industry and Information Technology of the People's Republic of China

Clinical Trial Data of Recombinant Human Albumin Injection (Oryza Sativa) was published in the journal “Gut”

"OsrHSA Recombinant Human AlbuminInjection provides a more accessible alternative for cirrhosis patients, especially in plasma-derived HSAresourcelimited regions," said the leading investigator of the study.

First-in-Class: Recombinant Human Albumin Injection (Oryza Sativa) Approved by China NMPA

Healthgen’s “Recombinant Human Albumin Injection(Oryza Sativa)” was approved by the China’s National Medical Products Administration (NMPA)on 18 July, 2025.